Seeking Alpha

Peregrine Pharmaceuticals (PPHM +8.7%) regains some yesterday's decline after the company was...

Peregrine Pharmaceuticals (PPHM +8.7%) regains some yesterday's decline after the company was featured in a pessimistic article in Seeking Alpha. The stock actually began its fall on Monday, but was exacerbated yesterday by the SA piece by contributor Robert Schwartz, who noted that PPHM's lead drug candidate, bavituximab, has had twelve Phase-I/-II studies and treated 613 cancer patients but has yet to observe a statistically significant improvement over a contemporary standard-of-care. Schwartz thinks its time to throw in the towel.
Comments (5)
  • And what is Schwartz position ?
    Are we to believe E. Lefevre ?
    27 Feb 2013, 12:17 PM Reply Like
  • The discussion is better than the article and has caused the stock to regain some ground it seems.
    27 Feb 2013, 12:21 PM Reply Like
  • The imaginary Mr. Swartz was a hedge fund creation and a stolen photo. Sorry if you bought into that horse ship.
    27 Feb 2013, 04:01 PM Reply Like
  • Robert Schwartz's position, must be as very pessimistic, SHORT rabid, but it seems that the action PPHM not pay much attention and up from yesterday over UN10%.
    28 Feb 2013, 11:03 AM Reply Like
  • ARNA INVESTOR: If Robert Schwartz is imaginary as you say and his photo is stolen, I would be surprised if one of the three federal agencies looking into the misconduct of CSM and the way they handled PPHM's Phase II data would not be interested to know this information.
    1 Mar 2013, 10:34 AM Reply Like
DJIA (DIA) S&P 500 (SPY)